Drug Profile
Cenobamate - SK biopharmaceuticals
Alternative Names: ONO-2017; ONTOZRY; X-Copri; XCOPRI; YKP-3089Latest Information Update: 18 Apr 2024
Price :
$50
*
At a glance
- Originator SK biopharmaceuticals
- Developer Angelini Pharmaceuticals; Arvelle Therapeutics; Endo Ventures; SK biopharmaceuticals; SK Life Science
- Class Analgesics; Antidepressants; Antiepileptic drugs; Anxiolytics; Carbamates; Chlorobenzenes; Mood stabilisers; Small molecules; Tetrazoles
- Mechanism of Action GABA A receptor modulators; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Partial epilepsies
- Phase III Tonic-clonic epilepsy
- Phase II Anxiety disorders; Bipolar disorders; Neuropathic pain
Most Recent Events
- 11 Apr 2024 US FDA approves cenobamate for alternate methods of administration for treatment of Partial epilepsies in USA
- 13 Mar 2024 SK biopharmaceuticals expects to launch for Partial epilepsies in Israel in April 2024
- 22 Jan 2024 Launched for Partial epilepsies (Adjunctive treatment) in Canada (PO)